Acura Pharmaceuticals Inc Revenue Growth Rates (ACUR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Acura Pharmaceuticals inc  (NASDAQ: ACUR)
 

ACUR's Revenue Growth by Quarter and Year

Acura Pharmaceuticals Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ACUR Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December 0.04
3rd Quarter September 0.27
2nd Quarter June 0.61
1st Quarter March 0.64
FY 1.56

ACURs Annual Revenue
Acura Pharmaceuticals Inc's Revenue in the fiscal year 2021 $ 1.56 millions
Acura Pharmaceuticals Inc's Revenue in the fiscal year 2020 $ 3.57 millions
Acura Pharmaceuticals Inc's Revenue in the fiscal year 2019 $ 2.66 millions
Acura Pharmaceuticals Inc's Revenue in the fiscal year 2018 $ 0.41 millions
Acura Pharmaceuticals Inc's Revenue in the fiscal year 2017 $ 2.97 millions




ACUR Revenue fourth quarter 2021 Y/Y Growth Comment
Acura Pharmaceuticals Inc reported drop in Revenue in the fourth quarter 2021 by -95% to $ 0.04 millions, from the same quarter in 2020.
The fall in the fourth quarter 2021 Acura Pharmaceuticals Inc's Revenue compares unfavorably to the Company's average Revenue doubling of 774.52%.

Looking into fourth quarter 2021 results within Major Pharmaceutical Preparations industry 235 other companies have achieved higher Revenue growth. While Acura Pharmaceuticals Inc' s Revenue meltdown of -95% ranks overall at the positon no. 3744 in the fourth quarter 2021.


ACUR Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December -95 % -40.98 % 1933.33 % -14.29 %
3rd Quarter September -34.15 % -68.94 % 1785.71 % -12.5 %
2nd Quarter June -54.81 % 2600 % -37.5 % -11.11 %
1st Quarter March -41.28 % 1457.14 % -65 % -92.65 %
FY   -56.41 % 34.21 % 548.78 % -

Financial Statements
Acura Pharmaceuticals Inc's fourth quarter 2021 Revenue $ 0.04 millions ACUR's Income Statement
Acura Pharmaceuticals Inc's fourth quarter 2020 Revenue $ 0.72 millions Quarterly ACUR's Income Statement


ACUR Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December -86.67 % 75.61 % -7.58 % -14.29 %
3rd Quarter September -55.74 % -69.63 % 2540 % -12.5 %
2nd Quarter June -4.69 % 23.85 % -28.57 % -60 %
1st Quarter March -11.11 % -10.66 % 16.67 % 185.71 %
FY (Year on Year)   -56.41 % 34.21 % 548.78 % -


Back to ACUR Growth rate Comparisons >> Back to ACUR Growth rate Comparisons >>


Revenue fourth quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #236
Healthcare Sector #549
Overall #3744

Revenue Y/Y Growth Statistics
High Average Low
12654.76 % 774.52 % -98.03 %
(Mar 31 2015)   (Dec 31 2017)
Revenue fourth quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #236
Healthcare Sector #549
Overall #3744
Revenue Y/Y Growth Statistics
High Average Low
12654.76 % 774.52 % -98.03 %
(Mar 31 2015)   (Dec 31 2017)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Acura Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2778.26 % 204.3 % -96.61 %
(Sep 30 2019)  


ACUR's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2021 Acura Pharmaceuticals Inc disclosed fall in Revenue from the third quarter by -86.67% to $ 0.04 millions, from $ 0.27 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2021 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 263 other companies have achieved higher Revenue quarter on quarter growth. While Acura Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 3866.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #264
Healthcare Sector #632
Overall #3866
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #264
Healthcare Sector #632
Overall #3866
Revenue Q/Q Growth Statistics
High Average Low
2778.26 % 204.3 % -96.61 %
(Sep 30 2019)  


ACUR's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2021 Acura Pharmaceuticals Inc disclosed fall in Revenue from the third quarter by -86.67% to $ 0.04 millions, from $ 0.27 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2021 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 263 other companies have achieved higher Revenue quarter on quarter growth. While Acura Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 3866.


Acura Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Dec 31 2020)
Cumulative Revenue 12 Months Ending $ 1.56 $ 2.25 $ 2.39 $ 3.12 $ 3.57
Y / Y Revenue Growth (TTM) -56.22 % -44.87 % -52.17 % -15.16 % 34.36 %
Year on Year Revenue Growth Overall Ranking # 1118 # 189 # 3556 # 2508 # 384
Seqeuential Revenue Change (TTM) -30.38 % -5.87 % -23.63 % -12.52 % -12.33 %
Seq. Revenue Growth (TTM) Overall Ranking # 3585 # 3208 # 3778 # 3535 # 3505


Cumulative Revenue growth Comment
Acura Pharmaceuticals Inc's cumulative 12 months Revenue continue to drop, but on the faster rate at -56.22% year on year, at Dec 31 2021 compare to the -44.87% decrease at Sep 30 2021. If the Acura Pharmaceuticals Inc's fiscal year would end at Dec 31 2021, annual Revenue would be $2 millions.

In the Healthcare sector 204 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 189 to 1118.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 185
Healthcare Sector # 205
Overall # 1118

Revenue TTM Y/Y Growth Statistics
High Average Low
1902.41 %
 246.41 %
-93.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 185
Sector # 486
S&P 500 # 3585
Cumulative Revenue growth Comment
Acura Pharmaceuticals Inc's cumulative 12 months Revenue continue to drop, but on the faster rate at -56.22% year on year, at Dec 31 2021 compare to the -44.87% decrease at Sep 30 2021. If the Acura Pharmaceuticals Inc's fiscal year would end at Dec 31 2021, annual Revenue would be $2 millions.

In the Healthcare sector 204 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 189 to 1118.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 185
Healthcare Sector # 205
Overall # 1118

Revenue TTM Y/Y Growth Statistics
High Average Low
1902.41 %
246.41 %
-93.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 185
Sector # 486
S&P 500 # 3585




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ACUR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Dec 31 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2021
Regenerx Biopharmaceuticals inc -0.01%$ -0.005 millions
Xtant Medical Holdings Inc -0.32%$ -0.321 millions
Biomarin Pharmaceutical Inc-0.51%$ -0.510 millions
Organon and Co -0.62%$ -0.620 millions
Healthcare Services Group Inc -0.65%$ -0.645 millions
Bausch Health Companies Inc -0.77%$ -0.768 millions
Tenet Healthcare Corp-1.20%$ -1.200 millions
Rockwell Medical inc -1.20%$ -1.203 millions
China Pharma Holdings Inc-1.42%$ -1.424 millions
Mimedx Group Inc -1.66%$ -1.662 millions
Adm Tronics Unlimited Inc -1.70%$ -1.703 millions
Marinus Pharmaceuticals Inc -1.75%$ -1.745 millions
Reshape Lifesciences Inc-2.00%$ -1.996 millions
Bicycle Therapeutics Plc-2.00%$ -2.001 millions
Zimmer Biomet Holdings Inc -2.27%$ -2.273 millions
Elanco Animal Health Incorporated-2.34%$ -2.343 millions
Gilead Sciences Inc -2.39%$ -2.385 millions
Axogen inc -2.95%$ -2.948 millions
Acorda Therapeutics Inc -3.12%$ -3.124 millions
Veru Inc -3.30%$ -3.297 millions
Merck and Co Inc -3.56%$ -3.564 millions
Neuronetics Inc -3.58%$ -3.575 millions
Biogen Inc -4.16%$ -4.165 millions
Inmed Pharmaceuticals Inc-4.23%$ -4.230 millions
Pharming Group N v -4.38%$ -4.378 millions
Notable Labs Ltd -4.39%$ -4.390 millions
Semler Scientific inc -4.40%$ -4.398 millions
Cv Sciences Inc -4.42%$ -4.424 millions
Meridian Bioscience Inc -4.92%$ -4.925 millions
Aclaris Therapeutics Inc -5.00%$ -5.000 millions


About Acura Pharmaceuticals Inc Revenue Growth Rates (ACUR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Acura Pharmaceuticals Inc (CIK 786947).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001410578-23-001462
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Acura Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.